Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. - Wikidata - awgldk - TriplyDB

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

http://www.wikidata.org/entity/Q38027061

about

Nucleot(s)ide analogues for hepatitis B virus-related hepatocellular carcinoma after curative treatment: a systematic review and meta-analysis Prevention of hepatocellular carcinoma in patients with chronic hepatitis B Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus Recent advances in micro/nanotechnologies for global control of hepatitis B infection Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.Hepatitis B virus: new therapeutic perspectives.The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.Hepatobiliary quiz-12 (2014).Chemopreventive strategies in hepatocellular carcinoma Hepatocellular carcinoma: clinical frontiers and perspectives.Postpartum care for mothers diagnosed with hepatitis B during pregnancy.Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China.Chronic hepatitis B virus infection and occurrence of hepatocellular carcinoma in tree shrews (Tupaia belangeri chinensis)Antiviral therapies and prospects for a cure of chronic hepatitis B.Antiviral therapies for hepatitis B virus-related hepatocellular carcinoma.Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria.Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.Hepatocellular carcinoma: From diagnosis to treatment.Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma.Establishment of drug-resistant HBV small-animal models by hydrodynamic injection Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy.Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B Efficacy of PEGylated Interferon in Treatment-Experienced Chinese Patients With HBeAg Positive Chronic Hepatitis B.Risk Assessment of Hepatocellular Carcinoma Using Transient Elastography Vs. Liver Biopsy in Chronic Hepatitis B Patients Receiving Antiviral Therapy.Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy.Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection.Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis.HBeAg-positive chronic hepatitis B: why do i treat my patients with Nucleos(t)ide analogs?Managing hepatitis B to prevent liver cancer: recent advances.Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.Associations between MTHFR Ala222Val polymorphism and risks of hepatitis and hepatitis-related liver cancer: a meta-analysis.Current treatment of hepatitis B virus infections.Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis.Hepatitis B: treatment choice and monitoring for response and resistance.Clinical Predictors for Neutrophil-to-Lymphocyte Ratio Changes in Patients with Chronic Hepatitis B Receiving Peginterferon Treatment.The miR-573/apoM/Bcl2A1-dependent signal transduction pathway is essential for hepatocyte apoptosis and hepatocarcinogenesis.Review article: novel therapies for hepatitis B virus cure - advances and perspectives.

P2860

Q26998178-B126C770-C5C5-4CD5-A092-5B90FFC877D2 Q27023997-B609E975-9E18-4F80-A285-AF133A13F944 Q28540372-12FC90CC-A5A8-4A18-81BA-DCD54449BE06 Q30375738-64D7FDC1-0224-451A-9EE9-281D28B31EFE Q30394611-87B1629F-4A03-4FFD-BEA6-5BCFB32F2296 Q30746254-2BD0AF5F-988F-4FE9-B4BB-C43B6929F64A Q34507250-3F841CA7-E6D9-433B-AF00-FC7A55A65613 Q34826535-B5BFD84D-19F4-464E-B85D-FF34B1403A9E Q34983479-7570FF05-4848-4463-8E46-B5290F1313D6 Q35101365-9EC943BD-FA3B-4662-A385-8327094D86F8 Q35112053-A3A46DD8-59A2-448B-A242-D5C0C0D6711C Q35137366-93C2C5E4-1E97-4E54-B7FB-526A5B550043 Q35173805-0670CC02-9308-4735-9A97-C3498044668F Q35204227-8B790EF2-602C-4146-A368-84D2276D20DE Q35245231-D73C63C0-6E15-46D9-9CD9-349F8B7DBB41 Q35270193-F0FB7B26-2771-47C0-8747-344D006E6AFC Q35304777-B59B7253-5BF8-468F-BFAE-F7F4A9A54C2A Q35402699-F685CE36-D449-4F41-8072-7D0DC073FA3A Q35668716-9988A21F-D59D-4464-99F4-B180181F038C Q35793292-B44BC1C1-E2AF-464E-90E4-F016CC378A4B Q36237555-72256501-203F-4B1A-A9BB-CD9F5664C465 Q36566914-48179F36-930F-4F56-828B-048549C0E62E Q36771967-86FABFCC-1598-4DE6-A852-9109D80F3430 Q36779207-683D67A4-39EA-4FAF-B401-F5C592EF53FB Q36954595-DD1311AB-0F43-4732-831F-7A822B3C186A Q37205302-7AACF187-600F-47BA-9A7A-9361E145DBB9 Q37241565-08A45A24-E6E8-4FAA-91D7-DF2364F430ED Q37266376-4B3A26FC-7400-4031-9DE6-5F0B41E64E25 Q37408920-633189C4-C422-4B50-814F-FCDFA9F92A3B Q38125450-8EE6E6F9-FF70-4082-AD97-9F48BED0F4BD Q38174258-C8BC8DA7-A890-44F3-9FCE-378408C94E68 Q38192050-BEB2946B-C3E5-41A8-A6B1-629673CA2349 Q38259534-62C7693D-02F1-44EC-AB97-4413B08146CF Q38403668-83304915-91D7-46FB-A209-B1796CEA9618 Q38553056-DEB461DB-B887-40F6-A1B7-761892344E5B Q38578909-B417987F-FC38-49B5-92DE-FF5CB9D8916D Q38707903-B49605D9-C1B7-403D-A6CF-CB2FFA800E9A Q38707994-1F922665-4B53-4182-B6CF-1196EFBAD0FC Q38850417-6908F4F5-EDA2-4A1F-8CAF-2E5404120AC0 Q38865511-2F195E2B-25A9-415C-A6F5-11DE4D50AD32

P2860

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

http://www.wikidata.org/entity/Q38027061

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

@en

type

label

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

@en

prefLabel

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

@en

P1433

Q38027061-658A97F5-7DD5-4DD4-A9A1-D56ED10F1847

P1476

Q38027061-29210C3B-F426-456F-BD30-E5F2ACE481CC

P2093

Q38027061-3A87769B-86E1-4862-A62B-AEF8EC23904D

Q38027061-D9C58B35-6553-42CF-978A-B6A09A696825

P2860

Q38027061-00936A24-8BA8-4E12-97EB-762FC1F9DF41

Q38027061-012596C4-A496-4B3D-892F-F800BC675A76

Q38027061-0C6FB76F-4C91-4337-B7E9-17500C838E23

Q38027061-11A8EC63-4E76-40E7-9D7B-65CF3DEDB664

Q38027061-12ECB448-C515-48A5-A19B-8359AFA8A3BB

Q38027061-1567EE7A-5878-4CEA-8361-452371DA40D4

Q38027061-181F2A32-84B4-466A-8655-20166F41EDDF

Q38027061-20AD6068-A946-4EEC-88CD-19A3B6BAD41D

Q38027061-234BBEBA-FDAD-401D-9822-B6B73AA32DE4

Q38027061-266BC73E-F79C-4313-9D76-D75546539E21

P304

Q38027061-1F1D066E-D872-43DA-8419-5440E88E32C9

P31

Q38027061-A77B4C1E-E7C0-4255-BD8C-CD31EA546A6A

P356

Q38027061-38A4120D-4059-4AD5-B07E-57A1F926BCB4

P407

Q38027061-E9B674EA-341A-44F9-9422-5C191A1A4437

P433

Q38027061-C1EA9283-4374-4028-96CD-9C584F7D4654

P478

Q38027061-A63E402C-7C2A-4D84-9EFB-304DC71FF397

P577

Q38027061-8CA13E71-D4E9-4182-A199-D1D51D2B167D

P5875

Q38027061-2BD946F3-C4E5-47EA-80E8-D3C9B477F8A1

P698

Q38027061-1A852E29-E64D-45BF-8DAE-B818FCEB4208

P356

P1433

P1476

Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

@en

P2093

Ching-Lung Lai

http://www.w3.org/2001/XMLSchema#string

Man-Fung Yuen

http://www.w3.org/2001/XMLSchema#string

P2860

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection.

Treatment of chronic hepatitis B.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis

Association of hepatitis B virus pre-S deletions with the development of hepatocellular carcinoma in chronic hepatitis B.

Hepatocellular carcinoma in the Asia pacific region.

Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis.

Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

P304

399-408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.25937

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229160443

http://www.w3.org/2001/XMLSchema#string

P698

22806323

http://www.w3.org/2001/XMLSchema#string